Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

The primary objective of this study is to compare progression-free survival (PFS) of patients with metastatic triple-negative breast cancer randomised to treatment with standard chemotherapy plus moxifloxacin or placebo.

Trial Details

NCT ID
NCT04722978
Phase
PHASE3
Sponsor
Sun Yat-Sen University Cancer Center
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Gemcitabine and carboplatin plus antibiotic (moxifloxacin)
  • Gemcitabine combined with carboplatin plus placebo
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.
  • Histologically confirmed invasive ductal carcinoma, no specific type (NOS)
  • ER negative and progesterone receptor (PR) negative (defined as \< 1% positive cells by IHC), human epidermal growth factor receptor 2 (HER2) negat…
  • No prior therapy after first recurrence or diagnosis of metastatic disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →